Is ProMIS Neurosciences Inc. (PMN) Halal?
Shariah Screening — 5 Standards
Based on financial data from December 2024
| Standard | Debt Ratio | Cash Ratio | Receivables | Income | Status |
|---|---|---|---|---|---|
| AAOIFI | 0.0% / 30% | 26.5% / 30% | 0.2% / 30% | N/A | ✓ HALAL |
| DJIM | 0.0% / 33% | 26.5% / 33% | 0.2% / 33% | N/A | ✓ HALAL |
| MSCI | 0.0% / 33% | 70.5% / 33% | 0.4% / 33% | N/A | ✗ NOT HALAL |
| S&P | 0.0% / 33% | 26.5% / 33% | 0.2% / 33% | N/A | ✓ HALAL |
| FTSE | 0.0% / 33% | 70.5% / 33% | 0.4% / 50% | N/A | ✗ NOT HALAL |
Financial Highlights
Profitability
| Gross Margin | 0.0% | |
| Operating Margin | 0.0% | |
| Net Margin | 0.0% | |
| Return on Equity (ROE) | -521.6% | |
| Return on Assets (ROA) | -178.7% |
Cash Flow & Balance Sheet
| Operating Cash Flow | -$27M |
| Free Cash Flow | -$27M |
| Current Ratio | 0.9 |
| Total Assets | $19M |
Price & Trading
| Last Close | $15.13 |
| 50-Day MA | $16.25 |
| 200-Day MA | $12.78 |
| Avg Volume | 179K |
| Beta | -0.4 |
|
52-Week Range
$6.27
| |
About ProMIS Neurosciences Inc. (PMN)
ProMIS Neurosciences, Inc. discovers and develops antibody therapies and therapeutic vaccines for neurodegenerative diseases and other misfolded protein diseases in Canada. The company's proprietary discovery platform comprises ProMIS and Collective Coordinates algorithms to predict novel targets known as disease specific epitopes on the molecular surface of misfolded proteins. Its lead product candidates comprise of PMN310, a monoclonal antibody (mAb) for toxic oligomers for treating Alzheimer's Disease; PMN267 for treatment of amyotrophic lateral sclerosis; and PMN442, a mAb targeting toxic a-syn oligomers and seeding fibrils for treating multiple system atrophy. The company also develops PNM440, an alpha-synuclein vaccine for treating multiple synucleinopathies; and PMN311, an amyloid-beta vaccine for treatment of Alzheimer's. In addition, it is developing therapies for frontotemporal lobar degeneration, Huntington's disease, progressive supranuclear palsy, corticobasal degeneration, and schizophrenia. The company was formerly known as Amorfix Life Sciences Ltd. and changed its name to ProMIS Neurosciences, Inc. in July 2015. ProMIS Neurosciences, Inc. is headquartered in Toronto, Canada.
Related Halal Stocks in Healthcare
Frequently Asked Questions
Is ProMIS Neurosciences Inc. (PMN) halal to invest in?
Based on our screening using AAOIFI Standard 21 (the strictest methodology), ProMIS Neurosciences Inc. is Halal. The company passes all financial ratio thresholds for debt, cash, receivables, and impermissible income. We screen against all 5 major standards: AAOIFI, DJIM, MSCI, S&P, and FTSE.
What is ProMIS Neurosciences Inc.'s debt ratio?
ProMIS Neurosciences Inc.'s debt ratio is 0.0% under the AAOIFI standard (which uses market capitalization as the denominator). The AAOIFI threshold is 30%. Under MSCI and FTSE (which use total assets as the denominator), the debt ratio is 0.0%.
What are ProMIS Neurosciences Inc.'s key financial metrics?
ProMIS Neurosciences Inc. has a market capitalization of $132M. Return on equity stands at -521.6%.
How often is the screening data updated?
Our screening data is updated regularly using the latest available financial statements and market data. Stock prices and market caps are refreshed frequently, while financial statements are updated quarterly when companies report earnings.
Disclaimer: HalalStockGuide.com provides Shariah compliance screening for educational and informational purposes only. This is not a fatwa, financial advice, or a recommendation to buy or sell any security. Screening results are based on publicly available financial data and established methodologies. Always consult a qualified Islamic scholar and a licensed financial advisor before making investment decisions.